The clinical significance of our findings is further supported by genome-wide bisulfite sequencing, revealing that co-administration of ERRα and DNMT1 inhibitors leads to promoter demethylation and re-expression of IRF4-encoding Interferon Regulatory Factor-4 and found herein to exhibit tumor-suppressor activity in BC cells. The gene discussed is IRF4; the disease is neoplasm.